Boehringer In­gel­heim, Zealand’s pos­i­tive Phase 2 MASH fi­bro­sis da­ta ‘un­in­ten­tion­al­ly’ re­leased

Boehringer In­gel­heim and Zealand Phar­ma’s sur­vo­du­tide has im­proved liv­er scar­ring in a Phase 2 test in pa­tients with meta­bol­ic dys­func­tion-as­so­ci­at­ed steato­hep­ati­tis, or MASH, ac­cord­ing to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER